Showing 91 - 100 of 94,844
Persistent link: https://www.econbiz.de/10014577795
Persistent link: https://www.econbiz.de/10014514650
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10012461130
Drug shortages are emerging as a major public health threat. Grave concern has been expressed by the medical community and government officials, and the crisis has been highlighted in recent media stories. Nevertheless, little has been written to date in the legal literature about the drug...
Persistent link: https://www.econbiz.de/10014173190
pharmaceuticals. While political attention currently focuses on compulsory licensing under TRIPS, this article examines the article 27 … to exclude certain pharmaceuticals from patentability in order to enable affordable access for those affected by diseases …
Persistent link: https://www.econbiz.de/10014224715
This paper explains how the current architecture of the pharmaceutical markets has created a misalignment of financial incentives and public health that is a central cause of harmful practices. It explores three possible solutions to address that misalignment: taxes, increased financial...
Persistent link: https://www.econbiz.de/10014156280
The pharmaceutical industry is one of the most innovative sectors in the world. In 2014, the global drug sales market exceeded one trillion dollars for the first time. Innovative, patented drugs represent the largest part of pharmaceutical sales revenues. Nowadays partnerships, licensing and M&A...
Persistent link: https://www.econbiz.de/10014105042
Physicians’ generic pharmaceutical adoption involves not only patients’ and insurance payers’ cost, but also their own interests. This study examines this double agency problem for physicians by using Taiwanese data because two of its institutional features: First, patients and physicians...
Persistent link: https://www.econbiz.de/10014129240
These are neither the best of times nor the worst of times for the pharmaceutical industry, or for global public health. Media reports regarding recent legal developments would suggest that the originator pharmaceutical industry is facing a new and dangerous threat to its long-term welfare,...
Persistent link: https://www.econbiz.de/10014141859
On August 30, 2003, the member countries of the WTO adopted the Decision on Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. This Decision provides flexibility for the export of pharmaceutical products under compulsory license (which flexibility...
Persistent link: https://www.econbiz.de/10014063513